Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up
Articolo
Data di Pubblicazione:
2019
Citazione:
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up / Fradet, Y; Bellmunt, J; Vaughn, Dj; Lee, Jl; Fong, L; Vogelzang, Nj; Climent, Ma; Petrylak, Dp; Choueiri, Tk; Necchi, A; Gerritsen, W; Gurney, H; Quinn, Di; Culine, S; Sternberg, Cn; Nam, K; Frenkl, Tl; Perini, Rf; de Wit, R; Bajorin, Df. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 30:6(2019), pp. 970-976. [10.1093/annonc/mdz127]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Fradet, Y; Bellmunt, J; Vaughn, Dj; Lee, Jl; Fong, L; Vogelzang, Nj; Climent, Ma; Petrylak, Dp; Choueiri, Tk; Necchi, A; Gerritsen, W; Gurney, H; Quinn, Di; Culine, S; Sternberg, Cn; Nam, K; Frenkl, Tl; Perini, Rf; de Wit, R; Bajorin, Df
Link alla scheda completa:
Pubblicato in: